International Edition
Latest News
Health

Huh Presents CRISPR Liquid Biopsy Data at AACR-KCA Conference

MUTE-Seq uses the CRISPR enzyme FnCas9-AF2 to selectively deplete normal cell-free DNA in blood samples, enriching rare cancer-derived mutations for detection, according to Bokuennews. The method compares pre- and post-processing results to filter errors. The foundational research was…

Huh Presents CRISPR Liquid Biopsy Data at AACR-KCA Conference

MUTE-Seq uses the CRISPR enzyme FnCas9-AF2 to selectively deplete normal cell-free DNA in blood samples, enriching rare cancer-derived mutations for detection, according to Bokuennews.

The method compares pre- and post-processing results to filter errors. The foundational research was published as a cover article in Advanced Materials and presented at the AACR annual meeting in 2023.

During follow-up, the two patients who relapsed both showed rising ctDNA levels; after subsequent treatment, levels fell in both. In one patient, ctDNA became undetectable over roughly one year of monitoring. In breast cancer research, ctDNA changes correlated with pathological response to neoadjuvant chemotherapy, and shifts were also observed with recurrence, disease progression, and subsequent therapy.

The team is now conducting multi-center clinical studies across eight solid tumor types, including colorectal, breast, lung, and pancreatic cancers. The Memorial Sloan Kettering Cancer Center (MSK) has selected the group as the MRD analysis partner for a prospective pancreatic cancer interventional trial.

To address the need for repeated testing after surgery or chemotherapy, the researchers developed a patient-tailored panel targeting about 40 mutations, reducing sequencing burden while maintaining sensitivity. The startup Geneseeq, which participated in the technology’s development, operates GMP-certified manufacturing facilities and a registered genetic testing laboratory for reagent production and specimen analysis.

A joint project with Geneseeq to develop a colorectal cancer MRD test based on MUTE-Seq was recently selected for the Ministry of SMEs and Startups’ Scale-up TIPS program, securing 3 billion won in government R&D funding over three years. The test, branded OncoDeepTrace, is currently undergoing evaluation as an innovative medical technology for colorectal cancer.

Huh said the presentation demonstrated both the technical precision and efficiency of the platform and clinical evidence that it reflects actual patient recurrence and treatment response. “Sharing these results with world-class researchers and discussing the future direction of liquid biopsy was highly meaningful,” he said.

He added that for precise testing to benefit patients, it must be economically sustainable and supported by a stable testing infrastructure, and that the team will continue building clinical evidence so more patients can access MUTE-Seq-based MRD testing.

About the author: Health Desk

Health Desk at Archynewsy.